Wells Fargo raises Progyny stock price target on strong sales growth
Wells Fargo raised its price target for Progyny (PGNY) to $38, citing strong sales growth and a record selling season. The company reported Q3 2026 revenue of $341M and adjusted EBITDA of $58M, beating estimates. Progyny's stock has returned 59% over the past year and currently trades at $30.10.
How this was made
The 30-second read
Why it matters
Analyst upgrades reinforce the earnings beat, likely prompting short‑term buying pressure.
Market read
New analyst price targets and guidance upgrades provide a fresh catalyst for PGNY, suggesting upside potential.
What to watch
Potential headwinds from employer cost‑containment and competitive pressure in the benefits space.
Background
Progyny reported Q3 2026 revenue of $341 M and adjusted EBITDA of $58 M, beating consensus, and narrowed its full‑year guidance range.
Ticker impact
Wells Fargo and Citizens raised their price targets on Progyny (PGNY) to $38, citing strong sales growth and beat earnings, providing fresh analyst guidance.
likely upward pressure as investors absorb the higher price target and improved guidance
The new $38 target is above the current $30.10 price and follows a beat on Q3 earnings, creating a clear catalyst for buying interest.
Market effects
Positive signal for the employee benefits/health benefits technology sector may lift peers.
U.S. market focus; limited regional spillover.
Modest; primarily affects U.S. listed health‑benefits tech stocks.
Counterpoint
The price target raise may be premature if sales growth slows; investors should watch upcoming guidance for Q4.
Key entities
- AnalystWells Fargo
Raised PGNY price target to $38, Overweight rating.
- AnalystCitizens
Raised PGNY price target to $38, Market Outperform rating.
